OnKure Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
45
- Stock Symbol
-
OKUR
- Investments
-
1
- Share Price
-
$2.58
- (As of Tuesday Closing)
OnKure Therapeutics General Information
Description
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Contact Information
Website
www.onkuretherapeutics.comCorporate Office
- 6707 Winchester Circle
- Suite 400
- Boulder, CO 80301
- United States
Corporate Office
- 6707 Winchester Circle
- Suite 400
- Boulder, CO 80301
- United States
OnKure Therapeutics Timeline
OnKure Therapeutics Stock Performance
As of 17-Nov-2026, OnKure Therapeutics’s stock price is $2.58. Its current market cap is $106M with 41.2M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.58 | $2.75 | $2.01 - $5.38 | $106M | 41.2M | 333K | -$2.26 |
OnKure Therapeutics Financials Summary
As of 30-Sep-2026, OnKure Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (63,237) | (30,354) | 38,716 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (65,165) | (62,120) | (53,724) | (36,374) |
| Net Income | (61,852) | (59,517) | (52,673) | (35,311) |
| Total Assets | 167,077 | 62,117 | 114,907 | 35,734 |
| Total Debt | 790 | 549 | 1,085 | 674 |
OnKure Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OnKure Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
OnKure Therapeutics Comparisons
Industry
Financing
Details
OnKure Therapeutics Competitors (90)
One of OnKure Therapeutics’s 90 competitors is Roche, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Roche | Corporation | Basel, Switzerland | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
OnKure Therapeutics Patents
OnKure Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169751-A1 | Compounds containing fused tricyclic rings as pi3k inhibitors | Pending | 07-Feb-2025 | ||
| WO-2026122515-A1 | Quinolizinones as pi3k inhibitors | Pending | 06-Dec-2024 | ||
| WO-2026112125-A1 | Benzopyridinones as pi3k inhibitors | Pending | 22-Nov-2024 | ||
| WO-2025255233-A1 | Compounds containing fused tricyclic rings as pi3k inhibitors | Pending | 07-Jun-2024 | ||
| WO-2025212360-A1 | Isoquinolones as pi3k inhibitors | Pending | 01-Apr-2024 | C07D401/14 |
OnKure Therapeutics Signals
OnKure Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OnKure Therapeutics Acquisitions (1)
OnKure Therapeutics’s most recent deal was a Merger/Acquisition with Reneo Pharmaceuticals. The deal was made on 04-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Reneo Pharmaceuticals | 04-Oct-2024 | Merger/Acquisition | Drug Discovery |
OnKure Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
OnKure Therapeutics FAQs
-
When was OnKure Therapeutics founded?
OnKure Therapeutics was founded in 2011.
-
Where is OnKure Therapeutics headquartered?
OnKure Therapeutics is headquartered in Boulder, CO.
-
What is the size of OnKure Therapeutics?
OnKure Therapeutics has 45 total employees.
-
What industry is OnKure Therapeutics in?
OnKure Therapeutics’s primary industry is Biotechnology.
-
Is OnKure Therapeutics a private or public company?
OnKure Therapeutics is a Public company.
-
What is OnKure Therapeutics’s stock symbol?
The ticker symbol for OnKure Therapeutics is OKUR.
-
What is the current stock price of OnKure Therapeutics?
As of 17-Nov-2026 the stock price of OnKure Therapeutics is $2.58.
-
What is the current market cap of OnKure Therapeutics?
The current market capitalization of OnKure Therapeutics is $106M.
-
Who are OnKure Therapeutics’s competitors?
Roche, BeOne Medicines, Novavax, GSK, and Genetix Biotherapeutics are some of the 90 competitors of OnKure Therapeutics.
-
What is OnKure Therapeutics’s annual earnings per share (EPS)?
OnKure Therapeutics’s EPS for 12 months was -$2.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process